

GUIDE TO BILLING AND CODING

Overview of relevant codes

INDICATIONS¹

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Crohn's Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults.

Ulcerative Colitis: SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.

SAFETY CONSIDERATIONS¹

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Drug-induced liver injury was reported in a patient with Crohn's disease during induction dosing of SKYRIZI. For the treatment of Crohn's disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks). Interrupt treatment with SKYRIZI if drug-induced liver injury is suspected, until this diagnosis is excluded. Avoid use of live vaccines in SKYRIZI patients.

Please see additional Important Safety Information on page 11.

Please click here for full [Prescribing Information](#).

OVERVIEW OF RELEVANT DERMATOLOGY AND RHEUMATOLOGY CODES

ICD-10-CM diagnosis codes²

Plaque psoriasis (Ps)

ICD-10-CM code	Description
L40.0	Psoriasis vulgaris
L40.8	Flexural psoriasis
L40.9	Psoriasis, unspecified

Psoriatic arthritis (PsA)

ICD-10-CM code	Description
L40.5	Arthropathic psoriasis
L40.50	Arthropathic psoriasis, unspecified
L40.51	Distal interphalangeal psoriatic arthropathy
L40.52	Psoriatic arthritis mutilans
L40.59	Other psoriatic arthropathy

Codes are shown for informational purposes only and are not intended to suggest the use of any drug that is inconsistent with FDA approval, or to function as reimbursement or legal advice. Providers should verify codes with third-party payers.

FDA=US Food and Drug Administration; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

Please see Indications and Important Safety Information on page 11.

Please click here for full [Prescribing Information](#).

Skyrizi® COMPLETE


Skyrizi®
risankizumab-rzaa

OVERVIEW OF RELEVANT GASTROENTEROLOGY CODES

ICD-10-CM diagnosis codes²

Crohn's disease (CD)

ICD-10-CM code	Description
K50.0-K50.019	Crohn's disease of small intestine
K50.1-K50.119	Crohn's disease of large intestine
K50.8-K50.819	Crohn's disease of both small and large intestine
K50.9-K50.919	Crohn's disease, unspecified

Ulcerative colitis (UC)

ICD-10-CM code	Description
K51.0-K51.019	Ulcerative (chronic) pancolitis
K51.2-K51.219	Ulcerative (chronic) proctitis
K51.3-K51.319	Ulcerative (chronic) rectosigmoiditis
K51.4-K51.419	Inflammatory polyps of colon
K51.5-K51.519	Left sided colitis
K51.8-K51.819	Other ulcerative colitis or unspecified

HCPCS codes^{1,3}

IV Infusion

HCPCS code	Description	Vial size	Dose	HCPCS units for J2327
J2327	Injection, risankizumab-rzaa, Intravenous, 1 mg	600 mg/10 mL	CD: 600 mg UC: 1200 mg	CD: 600 units UC: 1200 units

This product-specific J-Code was effective starting January 1, 2023; for IV induction dosing only.

Codes are shown for informational purposes only and are not intended to suggest the use of any drug that is inconsistent with FDA approval, or to function as reimbursement or legal advice. Providers should verify codes with third-party payers.

FDA=US Food and Drug Administration; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; IV=intravenous.

Please see Indications and Important Safety Information on page 11.

Please click here for full [Prescribing Information](#).

Skyrizi® COMPLETE

Skyrizi®
risankizumab-rzaa

DOSING AND NATIONAL DRUG CODES (NDC)

How do I provide my patients with SKYRIZI?

- A prescription is required for the SKYRIZI Prefilled Syringe 150 mg/mL, Pen 150 mg/mL, IV infusion 600 mg/10 mL, and SKYRIZI On-Body Injector (OBI) 360 mg/2.4 mL and 180 mg/1.2 mL
- The correct NDC must be used to ensure correct pharmacy dispensation
- To ensure your patient receives the appropriate SKYRIZI delivery device, please select a device type from the Enrollment and Prescription Form or when prescribing electronically

NDC¹

Electronic data exchange standards usually require the use of an 11-digit NDC. To convert these SKYRIZI 10-digit NDC to an 11-digit NDC, a leading zero is added to the first sequence of numbers (in the case of SKYRIZI, a 0 is added in front of 0074 to create 00074). Check with the payer to confirm the correct code required when billing for SKYRIZI.

INDICATION	SKYRIZI	10-digit NDC	11-digit NDC
Ps/PsA	Pen 150 mg/mL	0074-2100-01	00074-2100-01
	Prefilled Syringe 150 mg/mL	0074-1050-01	00074-1050-01
CD/UC	IV Infusion 600 mg/10 mL (60 mg/mL)	0074-5015-01	00074-5015-01
	On-Body Injector 360 mg/2.4 mL (150 mg/mL)	0074-1070-01	00074-1070-01
	On-Body Injector 180 mg/1.2 mL (150 mg/mL)	0074-1065-01	00074-1065-01

For additional guidance on coding, please refer to the Department of Health and Human Services Evaluation and Management Services Guide available at www.cms.gov

**For virtual or in-person support, call your Field Access Specialist,
or call 1.877.COMPLETE (1.877.266.7538)**

CD=Crohn's disease; IV=intravenous; Ps=plaque psoriasis; PsA=psoriatic arthritis; UC=ulcerative colitis.

SAFETY CONSIDERATIONS¹

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Drug-induced liver injury was reported in a patient with Crohn's disease during induction dosing of SKYRIZI. For the treatment of Crohn's disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks). Interrupt treatment with SKYRIZI if drug-induced liver injury is suspected, until this diagnosis is excluded. Avoid use of live vaccines in SKYRIZI patients.

Please see Indications and additional Important Safety Information on page 11.
Please click here for full [Prescribing Information](#).

Skyrizi® COMPLETE


Skyrizi®
risankizumab-rzaa

CMS-1500 AND CMS-1450 CODING GUIDE

Considerations when using codes

Healthcare provider services are generally billed using evaluation and management codes, which may be accompanied by prolonged service codes when appropriate.

For additional guidance on the appropriate use of prolonged service codes, please refer to the 2024 CPT® code book.

CMS-1500 and CMS-1450 commercial and Medicare coding^{4*}

Procedure type	Code
Office visit, new patient	99202-99205
Office visit, established patient	99211-99215
Prolonged service visit without direct patient contact by the physician or non-physician practitioner	99358, +99359 [†]
Hospital outpatient visit (CMS-1450, Medicare only)	G0463
Computed tomography (CT) scan	72125-72133, 72192-72194, 73200-73202, 73700-73702
Magnetic resonance imaging (MRI)	72141-72158, 72195-72197, 73218-73223, 73718-73723
X-ray imaging	72020-72120, 73000-73140, 73501-73660
Uric acid; blood	84550
Therapeutic, prophylactic, and diagnostic injections, IM/SC injection	96372
For PsA only	
Rheumatoid factor; qualitative	86430
For CD/UC only	
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	96413
Chemotherapy administration, intravenous infusion technique; each additional hour	+96415
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	96365
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	+96366

*The codes shown are only suggestions. The codes you need may vary by patient.

[†]93359 is for each additional 30 minutes after the first hour. Use only in conjunction with 93358.

CPT® is a registered trademark of the American Medical Association.

CD= Crohn's disease; CMS=Centers for Medicare & Medicaid Services; CPT®=Current Procedural Terminology; IM=intramuscular; PsA=psoriatic arthritis; SC=subcutaneous; UC=ulcerative colitis.

Please see Indications and Important Safety Information on page 11.

Please click here for full [Prescribing Information](#).

Skyrizi® COMPLETE

Skyrizi®
risankizumab-rzaa

CMS-1500 AND CMS-1450 CODING GUIDE (CONT'D)

Home infusion CPT® coding for CD/UC^{3,4*}

Patients with CD and UC may receive SKYRIZI in a home setting. In this setting, commercial payers reimburse providers separately for services and procedures. The products and services provided in the home setting are billed using the CMS-1500 claim form or its electronic claim equivalent.

This section provides general home infusion coding information for SKYRIZI. Coding for SKYRIZI may vary by commercial payer type and plan type. Contact payers for specific coding requirements for billing SKYRIZI.

Procedure type	Code
Home infusion/specialty drug administration, per visit (up to 2 hours)	99601
Home infusion/specialty drug administration, for each additional hour after 2 hours	+99602
Home infusion therapy, infusion therapy, not otherwise classified; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	S9379

*The codes shown above are for home infusion only. These will typically be used by the infusion provider.

Lab support CPT® coding for CD/UC⁴

Procedure type	CPT® code
Hepatic function panel test in which the blood levels of protein, albumin, alkaline phosphatase, bilirubin, and liver enzymes are measured	80076
Lab analysis measuring the amount of total bilirubin in a patient's blood	82247
Analysis measuring the amount of direct bilirubin in a patient's blood	82248

Considerations when using evaluation and management CPT® codes

Healthcare provider services are generally billed using evaluation and management codes, which may be accompanied by prolonged service codes when appropriate.

For additional guidance on the appropriate use of prolonged service codes, please refer to the 2024 CPT® code book.

CD=Crohn's disease; CMS=Centers for Medicare & Medicaid Services; CPT®=Current Procedural Terminology; UC=ulcerative colitis.

Please see Indications and Important Safety Information on page 11.
Please click here for full [Prescribing Information](#).

SKYRIZI® COMPLETE

SKYRIZI®
risankizumab-rzaa

COMPLETING A CMS-1500 FORM

Sample CMS-1500 form: use to submit claims to commercial insurance and Medicare for SKYRIZI administered in your office



HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

☐ PICA

1. MEDICARE ☐ MEDICAID ☐ TRICARE ☐ CHAMPVA ☐ GROUP HEALTH PLAN ☐ FECA BLK LUNG ☐ OTHER ☐

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE MM DD YY SEX M ☐ F ☐

5. PATIENT'S ADDRESS (No., Street)

6. PATIENT RELATIONSHIP TO INSURED
Self ☐ Spouse ☐ Child ☐ Other ☐

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:
a. EMPLOYMENT? (Current or Previous)
b. AUTO ACCIDENT?
c. OTHER ACCIDENT?

11. INSURED'S POLICY GROUP OR FECA NUMBER

12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY QUAL.

15. OTHER DATE MM DD YY QUAL.

16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE

18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

20. OUTSIDE LAB? ☐ YES ☐ NO \$ CHARGES

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24E) ICD Ind.

22. RESUBMISSION CODE ORIGINAL REF. NO.

23. AUTHORIZATION NUMBER

24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS MODIFIER E. DIAGNOSIS ICD-9-CM F. \$ CHARGES G. DAYS OR UNITS H. EPSON (Family Plan) I. ID. QUAL. J. RENDERING PROVIDER ID, #

25. FEDERAL TAX ID, NUMBER SSN EIN

26. PATIENT'S ACCOUNT NO.

27. ACCEPT ASSIGNMENT? ☐ YES ☐ NO

28. TOTAL CHARGE \$

29. AMOUNT PAID \$

30. Rsvd for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)

32. SERVICE FACILITY LOCATION INFORMATION

33. BILLING PROVIDER INFO & PH # ()

SIGNED DATE

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

CARRIER

PATIENT AND INSURED INFORMATION

PHYSICIAN OR SUPPLIER INFORMATION

Click here to download a copy of this form

CMS=Centers for Medicare & Medicaid Services.

Please see Indications and Important Safety Information on page 11.

Please click here for full [Prescribing Information](#).

Skyrizi COMPLETE

Skyrizi
risankizumab-rzaa

7

COMPLETING A CMS-1500 FORM (CONT'D)

If you are purchasing SKYRIZI from a distributor and need to submit a claim for reimbursement, you can use the CMS-1500 form.

- 1 Item 21:** Indicate the diagnosis using the appropriate ICD-10-CM code (see pages 2 and 3 for codes). The “ICD Ind” identifies the ICD-10-CM code set being reported. Enter 0 (zero) as a single digit between the vertical dotted lines.
- 2 Item 24A:** If line item NDC information is required, enter it in the shaded portion of Item 24A.
- 3 Item 24B:** Enter 11 (in place of a service code for physician offices).
- 4 Item 24D CPT/HCPCS:** Indicate appropriate CPT® and HCPCS codes. See pages 3, 5, and 6 of this guide for codes.
- 5 Item 24D MODIFIER (Use with CD/UC IV J-code only):** The JA Modifier may be required to indicate intravenous administration. Medicare plans require the JZ Modifier to attest that there was no discarded amount from a single vial. Providers should check with each plan to ensure appropriate coding.
Specific directions for CD/UC IV infusion:
 - J2327, enter the drug quantity in HCPCS units according to the dose, with 1 mg = 1 unit; each SKYRIZI single-dose vial is 600 mg and equal to 600 units for CD and 1200 units for UC
- 6 Item 24E:** Refer to the diagnosis for this service (see Item 21 above). Enter only 1 diagnosis pointer per line.
- 7 Item 24F:** Typically, enter average wholesale price (AWP), invoice price, or whichever price method is stated in your contract with the payer.
- 8 Item 24G:** Enter the number of units.
Specific directions for CD/UC IV infusion:
 - 96365: Enter 1 unit for the first hour of infusion
 - 96366: Enter 1 unit for each additional hour of infusion

Reminder: Under certain circumstances, qualified patients may acquire donated or no-cost drugs, or drugs may be covered under a pharmacy benefit and delivered to the administering provider (white bagging). When the drug is supplied by a third party, at no cost to the provider, it should NOT be billed to Medicare or any other payer.

However, the administration of the drug, regardless of the source, is a service that represents an expense to the physician. Therefore, administration of the drug is payable if the drug would have been covered if the physician purchased it. When reporting drug administration services for free-of-charge drugs, it may be necessary to include drug information on the claim and enter “0.01” charges. Payer policies may vary.

**For virtual or in-person support, call your Field Access Specialist,
or call 1.877.COMPLETE (1.877.266.7538)**

This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Providers are encouraged to contact third-party payers for specific information about their coverage policies.

CD=Crohn’s disease; CMS=Centers for Medicare & Medicaid Services; CPT®=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; IV=intravenous; NDC=National Drug Code; UC=ulcerative colitis.

Please see Indications and Important Safety Information on page 11.

Please click here for full [Prescribing Information](#).

Skyrizi® COMPLETE

Skyrizi®
risankizumab-rzaa

COMPLETING A CMS-1450 FORM

Sample CMS-1450 form: use to submit claims to commercial insurance and Medicare for SKYRIZI administered in a hospital outpatient setting

1		2		3a PAT. CNTL. # b. MED. REC. #		4 TYPE OF BILL	
5 FED. TAX NO.		6 STATEMENT COVERS PERIOD FROM		7 THROUGH			
8 PATIENT NAME		9 PATIENT ADDRESS					
10 BIRTHDATE		11 SEX		12 DATE		13 ADMISSION HR	
14 TYPE		15 SRC		16 DHR		17 STAT	
18		19		20		21	
22		23		24		25	
26		27		28		29 ACCT STATE	
30		31 OCCURRENCE DATE		32 CODE		33 OCCURRENCE DATE	
34 CODE		35 OCCURRENCE DATE		36 CODE		37 OCCURRENCE DATE	
38		39 VALUE CODES AMOUNT		40 CODE		41 VALUE CODES AMOUNT	
42		43		44		45	
46		47		48		49	
50		51		52		53	
54		55		56		57	
58		59		60		61	
62		63		64		65	
66		67		68		69	
70		71		72		73	
74		75		76		77	
78		79		80		81	
82		83		84		85	
86		87		88		89	
90		91		92		93	
94		95		96		97	
98		99		100		101	
102		103		104		105	
106		107		108		109	
110		111		112		113	
114		115		116		117	
118		119		120		121	
122		123		124		125	
126		127		128		129	
130		131		132		133	
134		135		136		137	
138		139		140		141	
142		143		144		145	
146		147		148		149	
150		151		152		153	
154		155		156		157	
158		159		160		161	
162		163		164		165	
166		167		168		169	
170		171		172		173	
174		175		176		177	
178		179		180		181	
182		183		184		185	
186		187		188		189	
190		191		192		193	
194		195		196		197	
198		199		200		201	
202		203		204		205	
206		207		208		209	
210		211		212		213	
214		215		216		217	
218		219		220		221	
222		223		224		225	
226		227		228		229	
230		231		232		233	
234		235		236		237	
238		239		240		241	
242		243		244		245	
246		247		248		249	
250		251		252		253	
254		255		256		257	
258		259		260		261	
262		263		264		265	
266		267		268		269	
270		271		272		273	
274		275		276		277	
278		279		280		281	
282		283		284		285	
286		287		288		289	
290		291		292		293	
294		295		296		297	
298		299		300		301	
302		303		304		305	
306		307		308		309	
310		311		312		313	
314		315		316		317	
318		319		320		321	
322		323		324		325	
326		327		328		329	
330		331		332		333	
334		335		336		337	
338		339		340		341	
342		343		344		345	
346		347		348		349	
350		351		352		353	
354		355		356		357	
358		359		360		361	
362		363		364		365	
366		367		368		369	
370		371		372		373	
374		375		376		377	
378		379		380		381	
382		383		384		385	
386		387		388		389	
390		391		392		393	
394		395		396		397	
398		399		400		401	
402		403		404		405	
406		407		408		409	
410		411		412		413	
414		415		416		417	
418		419		420		421	
422		423		424		425	
426		427		428		429	
430		431		432		433	
434		435		436		437	
438		439		440		441	
442		443		444		445	
446		447		448		449	
450		451		452		453	
454		455		456		457	
458		459		460		461	
462		463		464		465	
466		467		468		469	
470		471		472		473	
474		475		476		477	
478		479		480		481	
482		483		484		485	
486		487		488		489	
490		491		492		493	
494		495		496		497	
498		499		500		501	
502		503		504		505	
506		507		508		509	
510		511		512		513	
514		515		516		517	
518		519		520		521	
522		523		524		525	
526		527		528		529	
530		531		532		533	
534		535		536		537	
538		539		540		541	
542		543		544		545	
546		547		548		549	
550		551		552		553	
554		555		556		557	
558		559		560		561	
562		563		564		565	
566		567		568		569	
570		571		572		573	
574		575		576		577	
578		579		580		581	
582		583		584		585	
586		587		588		589	
590		591		592		593	
594		595		596		597	
598		599		600		601	
602		603		604		605	
606		607		608		609	
610		611		612		613	
614		615		616		617	
618		619		620		621	
622		623		624		625	
626		627		628		629	
630		631		632		633	
634		635		636		637	
638		639		640		641	
642		643		644		645	
646		647		648		649	
650		651		652		653	
654		655		656		657	
658		659		660		661	
662		663		664		665	
666		667		668		669	
670		671		672		673	
674		675		676		677	
678		679		680		681	
682		683		684		685	
686		687		688		689	
690		691		692		693	
694		695		696		697	
698		699		700		701	
702		703		704		705	
706		707		708		709	
710		711		712		713	
714		715		716		717	
718		719		720		721	
722		723		724		725	
726		727		728		729	
730		731		732		733	
734		735		736		737	
738		739		740		741	
742		743		744		745	
746		747		748		749	
750		751		752		753	
754		755		756		757	
758		759		760		761	
762		763		764		765	
766		767		768		769	
770		771		772		773	
774		775		776		777	
778		779		780		781	
782		783		784		785	
786		787		788		789	
790		791		792		793	
794		795		796		797	
798		799		800		801	
802		803		804		805	
806		807		808		809	
810		811		812		813	
814		815		816		817	
818		819		820		821	
822		823		824		825	
826		827		828		829	
830		831		832		833	
834		835		836		837	
838		839		840		841	
842		843		844		845	
846		847		848		849	
850		851		852		853	
854		855		856		857	
858		859		860		861	
862		863		864		865	
866		867		868		869	
870		871		872		873	
874		875		876		877	
878		879		880		881	
882		883		884		885	
886		887		888		889	

COMPLETING A **CMS-1450 FORM** (CONT'D)

If you are purchasing SKYRIZI from a distributor and need to submit a claim for reimbursement, you can use the CMS-1450 form.

- 1** **Locator Box 42:** List revenue codes in ascending order.
- 2** **Locator Box 43:** Enter narrative description of corresponding revenue code (eg, clinic, lab general). If line item NDC information is required, enter it in the unshaded portions of Locator Box 43. Payer requirements for NDC entries may vary.
- 3** **Locator Box 44:** Indicate appropriate CPT® and HCPCS codes as required by the payer. See pages 3, 5, and 6 of this guide for codes.
Specific directions for CD/UC IV infusion:
 - J2327, enter the drug quantity in HCPCS units according to the dose, with 1 mg = 1 unit; each SKYRIZI single-dose vial is 600 mg and equal to 600 units for CD and 1200 units for UC
- 4** **Locator Box 46:** Enter the number of units.
Specific directions for CD/UC IV infusion:
 - 96365: Enter 1 unit for the first hour of infusion
 - 96366: Enter 1 unit for each additional hour of infusion
- 5** **Locator Box 67:** Indicate the diagnosis using the ICD-10-CM code that supports medical justification for Crohn's disease or ulcerative colitis (see page 3 for ICD-10-CM codes).

Reminder: Under certain circumstances, qualified patients may acquire donated or no-cost drugs, or drugs may be covered under a pharmacy benefit and delivered to the administering provider (white bagging). When the drug is supplied by a third party, at no cost to the provider, it should NOT be billed to Medicare or any other payer.

However, the administration of the drug, regardless of the source, is a service that represents an expense to the physician. Therefore, administration of the drug is payable if the drug would have been covered if the physician purchased it. When reporting drug administration services for free-of-charge drugs, it may be necessary to include drug information on the claim and enter "0.01" charges. Payer policies may vary.

**For virtual or in-person support, call your Field Access Specialist,
or call 1.877.COMPLETE (1.877.266.7538)**

This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Providers are encouraged to contact third-party payers for specific information about their coverage policies.

CD=Crohn's disease; CMS=Centers for Medicare & Medicaid Services; CPT®=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; IV=intravenous; NDC=National Drug Code; UC=ulcerative colitis.

Please see Indications and Important Safety Information on page 11.

Please click here for full [Prescribing Information](#).

Skyrizi® COMPLETE

Skyrizi®
risankizumab-rzaa

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR SKYRIZI® (risankizumab-rzaa)

INDICATIONS¹

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Crohn's Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults.

Ulcerative Colitis: SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.

IMPORTANT SAFETY INFORMATION¹

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Hepatotoxicity in Treatment of Inflammatory Bowel Disease

Drug-induced liver injury was reported in a patient with Crohn's disease who was hospitalized for a rash during induction dosing of SKYRIZI. For the treatment of Crohn's disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks); monitor thereafter according to routine patient management. Consider an alternate treatment for patients with evidence of liver cirrhosis. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct your patient to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age-appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI in plaque psoriasis and psoriatic arthritis include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

Most common (>3%) adverse reactions associated with SKYRIZI in Crohn's disease are upper respiratory infections, headache, and arthralgia in induction, and arthralgia, abdominal pain, injection site reactions, anemia, pyrexia, back pain, arthropathy, and urinary tract infection in maintenance.

Most common (≥3%) adverse reactions associated with SKYRIZI in ulcerative colitis are arthralgia in induction, and arthralgia, pyrexia, injection site reactions, and rash in maintenance.

Lipid Elevations: Increases from baseline and increases relative to placebo were observed at Week 4 and remained stable to Week 12 in patients treated with SKYRIZI in Crohn's disease. Lipid elevations observed in patients with ulcerative colitis were similar to those in Crohn's disease.

Dosage Forms and Strengths: SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL single-dose vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

References: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc. 2. Centers for Medicare & Medicaid Services. 2024 ICD-10-CM. 2024 Code Tables, Tabular and Index. Updated February 1, 2024. Accessed February 21, 2024. <https://www.cms.gov/medicare/coding-billing/icd-10-codes/2024-icd-10-cm> 3. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) quarterly update. Centers for Medicare and Medicaid Services website. Accessed April 9, 2024. <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update> 4. American Medical Association. Current Procedural Terminology: CPT® 2024: Professional Edition. Chicago, IL: AMA Press; 2023.

Please click here for full [Prescribing Information](#).

abbvie

© 2024 AbbVie. All rights reserved.
SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd.
US-SKZG-240268 June 2024


Skyrizi®
risankizumab-rzaa